May 2018 in “The Journal of urology/The journal of urology” The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.
Isotretinoin and tazarotene help treat acne, while minoxidil and finasteride promote hair growth.
January 2019 in “Arabian Journal of Chemistry” Method found to accurately identify finasteride impurities using liquid chromatography.
January 2020 in “Asian journal of applied science and technology” Good nutrition is crucial for health and preventing disease, and supplements can help prevent nutrient deficiencies.
October 1999 in “The Journal of Urology” New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
July 1993 in “Inpharma Weekly” Dicentrine reduced heart disease risk factors in rats, T-588 protected mice brains without side effects, Provir blocked herpes virus and lessened mouse symptoms, and LY191704 could treat hair loss and prostate issues.
75 citations,
November 2016 in “Medicines” Beta-sitosterol has potential health benefits but needs more research to fully understand its effects and improve its use in treatments.
54 citations,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
21 citations,
August 2016 in “Translational Andrology and Urology” Delayed ejaculation is a complex issue caused by psychological, biological, and lifestyle factors, requiring a holistic treatment approach.
13 citations,
August 1997 in “Steroids” Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.
12 citations,
May 2010 in “PubMed” No definitive link between finasteride and male breast cancer, but further research is needed.
12 citations,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
3 citations,
October 1995 in “Southern Medical Journal” Finasteride may cause breast enlargement, low testosterone a risk factor.
1 citations,
August 2017 in “The Journal of urology/The journal of urology” 5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
September 2024 in “Frontiers in Neuroendocrinology” 5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.
June 2024 in “Ecotoxicology and Environmental Safety” Finasteride harms Daphnia magna's reproduction, growth, and metabolism.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
March 2011 in “European Urology Supplements” Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.
May 2022 in “The Journal of Sexual Medicine” Finasteride is linked to sexual dysfunction, especially in younger men using it for hair loss.
August 2021 in “The Journal of Urology” Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
January 2018 in “International Journal of Medical Research and Health Sciences” Finasteride reduces blood loss and the need for blood transfusions during and after TURP surgery.
October 2005 in “Archives of Dermatological Research” Large prostate patients more likely to have hair loss.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
35 citations,
February 1994 in “Fundamental and applied toxicology” High doses of finasteride cause cell growth and tumors in mice.
30 citations,
January 2008 in “The Aging Male” The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
22 citations,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
3 citations,
January 1994 in “Toxicological Sciences” Finasteride causes abnormal growth in male mice cells at high doses.
6 citations,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.